Sign in

CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
operating
EIN
823562771
Phone
(650) 457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$111,656
in 2 filings

Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Douglas Earl Martin −$63K SVP, General Counsel sold 6% of stake
  2. Parker Geoffrey M. −$49K CHIEF FINANCIAL OFFICER sold 3% of stake

Reading 47 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2020-04-24 Chang David D President and CEO Other acquisition +9,198 1,201,108
2020-04-24 Chang David D President and CEO Other acquisition +9,187 2,224,101
2020-03-18 Chang David D President and CEO Gift +428,022 650,266
2020-03-18 Chang David D President and CEO Gift +428,022 650,266
2020-03-18 Belldegrun Arie Director Grant or award · Stock Option (Right to Buy) +379,066 379,066
2020-03-18 Chang David D President and CEO Grant or award · Stock Option (Right to Buy) +568,600 568,600
2020-03-18 MOORE ALISON Chief Technical Officer Grant or award +30,800 93,821
2020-03-18 MOORE ALISON Chief Technical Officer Grant or award · Stock Option (Right to Buy) +109,600 109,600

Page 18 of 18 · 348 trades